SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Apr 28, 2016
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: April 28, 2016 · CIK: 0001659617 · Accession: 0001144204-16-097013
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-209323
Letter
Re: Moleculin Biotech, Inc. Registration Statement No. 333-209323
[LETTERHEAD OF BONWICK CAPITAL]
April 28, 2016
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-3628
Attn: Scot Foley, Esq., Staff Attorney
Division of Corporation Finance
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Daylight Time, on May 2, 2016, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 160 copies of the Preliminary Prospectus dated April 26, 2016 (the “Preliminary Prospectus”), through the date hereof, to dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, as sole underwriter we confirm that we are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
BONWICK CAPITAL PARTNERS LLC
Show Raw Text
CORRESP
1
filename1.htm
[LETTERHEAD OF BONWICK CAPITAL]
April 28, 2016
United States Securities and Exchange
Commission
100 F Street, N.E.
Washington, DC 20549-3628
Attn: Scot Foley, Esq., Staff Attorney
Division of Corporation Finance
Re: Moleculin Biotech, Inc. Registration Statement No. 333-209323
In connection
with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”),
we hereby join in the request of Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement
be accelerated so that it will be declared effective at 4:30 p.m., Eastern Daylight Time, on May 2, 2016, or as soon as practicable
thereafter.
Pursuant to Rule
460 under the Act, please be advised that we have distributed approximately 160 copies of the Preliminary Prospectus dated April
26, 2016 (the “Preliminary Prospectus”), through the date hereof, to dealers, institutions and others.
In connection
with the Preliminary Prospectus distribution for the above-referenced issue, as sole underwriter we confirm that we are complying
with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
BONWICK CAPITAL PARTNERS LLC
By: /s/ Devin Wicker
Devin Wicker
CEO
Bonwick Capital Partners
40 W 57th street, 28th floor
New York, NY 10019